AVEO Pharmaceuticals, Inc.

NasdaqCM:AVEO Stock Report

Market Cap: US$521.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

AVEO Pharmaceuticals Management

Management criteria checks 3/4

Key information

Michael Bailey

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage20.0%
CEO tenure8yrs
CEO ownership1.0%
Management average tenure2.7yrs
Board average tenure8yrs

Recent management updates

Recent updates

AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash

Oct 18

Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money

Oct 04
Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money

A Current Assessment On AVEO Pharmaceuticals

Aug 15

Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt

Jun 21
Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt

AVEO Pharmaceuticals Is Primed For A Breakout

May 24

Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results

Mar 17
Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results

AVEO Pharmaceuticals: Finally Ready To Reboot

Mar 09

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Mar 03
AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 23
AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

AVEO Pharmaceuticals: Sticking To The Plan

Oct 29

AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment

Jul 24

AVEO Oncology: Time To Be Patient

Jun 07

AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication

Jan 07

AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA

Dec 27

CEO Compensation Analysis

How has Michael Bailey's remuneration changed compared to AVEO Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$3mUS$590k

-US$53m

Sep 30 2021n/an/a

-US$58m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$2mUS$565k

-US$36m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$452k

Dec 31 2019US$2mUS$528k

US$9m

Sep 30 2019n/an/a

US$36m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

US$4m

Dec 31 2018US$3mUS$528k

-US$5m

Sep 30 2018n/an/a

-US$24m

Jun 30 2018n/an/a

-US$28m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$1mUS$480k

-US$65m

Sep 30 2017n/an/a

-US$74m

Jun 30 2017n/an/a

-US$53m

Mar 31 2017n/an/a

-US$28m

Dec 31 2016US$1mUS$444k

-US$27m

Compensation vs Market: Michael's total compensation ($USD2.94M) is about average for companies of similar size in the US market ($USD2.52M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Bailey (57 yo)

8yrs

Tenure

US$2,943,905

Compensation

Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Bailey
CEO, President & Director8yrsUS$2.94m0.98%
$ 5.1m
Erick Lucera
Chief Financial Officer3yrsUS$1.24m0%
$ 0
Michael Ferraresso
Chief Commercial Officerno dataUS$1.25m0.038%
$ 200.0k
Jeb Ledell
Chief Operating Officer1.1yrsno data0%
$ 0
Danielle Holland
VP of Legal & Corporate Secretary2yrsno datano data
Kevin Peacock
Senior Vice President of Marketing3.2yrsno datano data
David Crist
Vice President of Sales2.3yrsno datano data
Catherine DeRose
Vice President of Human Resources2.3yrsno datano data
Lisa Bruneau
VP of Finance & Treasurer7yrsno datano data

2.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: AVEO's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Bailey
CEO, President & Director8yrsUS$2.94m0.98%
$ 5.1m
Anthony Evnin
Independent Director20.8yrsUS$127.61k0.12%
$ 627.6k
Kenneth Bate
Independent Chairman15.1yrsUS$158.73k0.0011%
$ 5.6k
Raju Kucherlapati
Member of Scientific Advisory Boardno dataUS$3.00kno data
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
H. Horvitz
Member of Scientific Advisory Boardno datano datano data
Tyler Jacks
Member of Scientific Advisory Boardno datano datano data
Lynda Chin
Member of Scientific Advisory Boardno datano datano data
Lewis Cantley
Member of Scientific Advisory Boardno datano datano data
Gregory Mayes
Independent Director3.9yrsUS$120.61k0%
$ 0
Douglas Hanahan
Member of Scientific Advisory Boardno datano datano data
Scarlett Spring
Independent Director3.2yrsUS$126.84k0%
$ 0

8.0yrs

Average Tenure

63yo

Average Age

Experienced Board: AVEO's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/21 03:42
End of Day Share Price 2023/01/19 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AVEO Pharmaceuticals, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)